Bhargava Samir, Dubey Satya Prakash, Haldipur Deepak, Hathiram Bachi, Jagtap Charuhas, Khattar Vicky, Kulkarni Shriram Vasant, Kotamkar Ashwin, Muralidharan Parthasarathy, Kumar Pradeep, Qamra Amit, Ramadhin Abhishek, Venkatraman Sreenivasan
Bhargava ENT Clinic, Mumbai, India.
Divya Advanced ENT Clinic, Bhopal, India.
Indian J Otolaryngol Head Neck Surg. 2023 Sep;75(3):2672-2680. doi: 10.1007/s12070-023-03708-2. Epub 2023 Mar 28.
Recurrent aphthous stomatitis (RAS) is characterized by painful, oral mucosal ulcers with wide range of prevalence ranging from 2 to 78%. Etiology of RAS is idiopathic and multifactorial. There are numerous gaps in assessment and management of RAS and the absence of guidelines or a consensus document makes the treatment further difficult. The aim of this document is to provide an Indian expert consensus for management of RAS. Experts from different specialties such as Otorhinolaryngology, Oral Medicine/Dentistry and Internal Medicine from India were invited for face to face and online meetings. After a deliberate discussion of current literature, evidence and clinical practice during advisory meetings, experts developed a consensus for management of RAS. We identify that the prevalence of RAS may lie between 2 and 5%. In defining RAS, we advocate three or more recurrences of aphthous ulcers per year as criterion for RAS. Investigation should include basic hematological (complete blood count) and nutritional (serum vitamin B12, and iron studies) parameters. Primary aim of treatment is to reduce the pain, accelerate ulcer healing, reduce the recurrences and improve the quality of life. In treating RAS, initial choice of medications is determined by pain intensity, number and size of ulcers and previous number of recurrences. Topical and systemic agents can be used in combination for effective relief. In conclusion, this consensus will help physicians and may harmonize effective diagnosis and treatment of RAS.
复发性阿弗他口炎(RAS)的特征是口腔黏膜出现疼痛性溃疡,其患病率范围广泛,从2%到78%不等。RAS的病因不明且具有多因素性。在RAS的评估和管理方面存在许多空白,并且缺乏指南或共识文件使得治疗更加困难。本文件的目的是为RAS的管理提供一份印度专家共识。邀请了来自印度不同专业领域的专家,如耳鼻喉科、口腔医学/牙科和内科专家,参加面对面和在线会议。在咨询会议期间,经过对当前文献、证据和临床实践的深入讨论,专家们制定了RAS管理的共识。我们确定RAS的患病率可能在2%至5%之间。在定义RAS时,我们主张以每年复发性阿弗他溃疡发作三次或更多次作为RAS的标准。检查应包括基本血液学(全血细胞计数)和营养(血清维生素B12和铁研究)参数。治疗的主要目标是减轻疼痛、加速溃疡愈合、减少复发并改善生活质量。在治疗RAS时,药物的初始选择取决于疼痛强度、溃疡的数量和大小以及既往复发次数。局部和全身用药可联合使用以有效缓解症状。总之,这一共识将有助于医生,并可能使RAS的有效诊断和治疗更加协调一致。